MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...

When Xiao Wang applied to faculty jobs, many of the institutions where she interviewed thought her research proposal - to ...

Biomedical engineers at Duke University have demonstrated a new synthetic approach that turbocharges bacteria into producing ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

Our closest relationships promise us great rewards and we enrich them by bringing a full representation of who we are.

Oligonucleotide therapies are among the most promising biological therapeutics. They target disease at a different stage of ...

NIH grant recipients receive additional funding to cover "indirect costs," such as building maintenance and administrative ...

Leonardo da Vinci understood the power of melding human thinking and creation with nature’s intelligence—an approach to ...